Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

FDA approvals 2017

- PMLiVE

Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

This is the most common type of non-Hodgkin lymphoma worldwide

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

EU flag

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

Gilead Sciences and Kymera enter oncology partnership worth up to $750m

The companies will focus on advancing Kymera’s oral molecular glue degrader programme

- PMLiVE

Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE

GSK’s Blenrep combinations approved by MHRA to treat multiple myeloma

Approximately 6,500 new cases of the blood cancer are diagnosed in the UK each year

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

Up to 160,000 people in the US are affected by polycythaemia vera

- PMLiVE

Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

Primary biliary cholangitis affects approximately 163,000 people in Europe

- PMLiVE

Pfizer granted FDA approval for Adcetris combination in large B-cell lymphoma

Up to 70% of patients with this form of non-Hodgkin lymphoma are diagnosed with advanced disease

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

- PMLiVE

Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

The company gained access to the drug through its $4.3bn acquisition of CymaBay

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links